Enterprise Value
140M
Cash
80.64M
Avg Qtr Burn
-58.66M
Short % of Float
11.98%
Insider Ownership
0.89%
Institutional Own.
0.64%
Qtr Updated
06/30/23
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
SP-102 (SEMDEXA™) Details Sciatica , Spine disorder | NDA FDA meeting | |
STI-5656 (Abivertinib Maleate) (BTK and EGFR inhibitor) Details Lung disease, Lung cancer, Non-small cell lung carcinoma, Cancer | Phase 3 Data readout | |
OVYDSO (STI-1558) Details COVID-19 | Phase 3 Initiation | |
SP-103 Details Chronic lower back pain | Phase 2 Data readout | |
Phase 2 Data readout | ||
COVI-DROPS Details COVID-19 | Phase 2 Data readout | |
STI-1499 (COVIGUARD™) Details COVID-19 | Phase 1 Data readout | |
Abivertinib Maleate (Fujovee) (STI-5656) (BTK inhibitor) Details Solid tumor/s, Cancer, Prostate cancer, Castration-resistant prostate cancer | Failed Discontinued | |
Failed Discontinued | ||
STI-3031 (anti-Pd-L1 antibody) Details Urothelial cancer, Cancer | Failed Discontinued | |
Failed Discontinued | ||
STI-2020 (COVI-AMG) Details COVID-19, Solid tumor/s | Failed Discontinued |